• 1. An integrated droplet-digital microfluidic system for on-demand droplet creation, mixing, incubation, and sorting?
  Lab Chip, 2019,19, 524-535
• 2. An aptamer-based keypad lock system?
  Yaqing Liu,Jiangtao Ren,Jing Li,Jiyang Liu,Erkang Wang Chem. Commun., 2012,48, 802-804
• 3. Achieving high-efficiency purely organic room-temperature phosphorescence materials by boronic ester substitution of phenoxathiine?
  Mengke Li,Xinyi Cai,Zhenyang Qiao,Wentao Xie,Liangying Wang,Nan Zheng,Shi-Jian Su Chem. Commun., 2019,55, 7215-7218
• 4. An anti-leakage liquid metal thermal interface material
  Kaiyuan Huang,Wangkang Qiu,Meilian Ou,Xiaorui Liu,Zenan Liao,Sheng Chu RSC Adv., 2020,10, 18824-18829
• 5. Aggregation-induced emission enhancement of carbon quantum dots and applications in light emitting devices
  Rongyan Guo,Tao Li,Shuie Shi J. Mater. Chem. C, 2019,7, 5148-5154

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridine carboxaldehydes

Recent Advances in the Application of 6-Bromo-5-chloropyridine-3-carbaldehyde (CAS: 1228898-23-4) in Chemical Biology and Pharmaceutical Research

6-Bromo-5-chloropyridine-3-carbaldehyde (CAS: 1228898-23-4) is a versatile heterocyclic building block that has garnered significant attention in recent chemical biology and pharmaceutical research. This compound, characterized by its reactive aldehyde group and halogen substituents, serves as a critical intermediate in the synthesis of various bioactive molecules. Recent studies have highlighted its utility in drug discovery, particularly in the development of kinase inhibitors and antimicrobial agents. The unique electronic properties imparted by the bromo and chloro substituents make this compound particularly valuable for cross-coupling reactions and further functionalization.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the use of 6-bromo-5-chloropyridine-3-carbaldehyde as a key precursor in the synthesis of novel Bruton's tyrosine kinase (BTK) inhibitors. The researchers utilized the aldehyde functionality to introduce diverse pharmacophores through reductive amination reactions, yielding compounds with improved selectivity profiles. Molecular docking studies revealed that derivatives containing this core structure exhibited enhanced binding affinity to the BTK active site, with IC50 values in the low nanomolar range.

In antimicrobial research, a team at the University of Manchester recently reported (2024, Bioorganic & Medicinal Chemistry Letters) the development of potent antibacterial agents derived from 6-bromo-5-chloropyridine-3-carbaldehyde. The compound served as the starting material for a series of Schiff base derivatives that showed remarkable activity against multidrug-resistant Staphylococcus aureus strains. The presence of both halogen atoms was found to be crucial for maintaining membrane permeability, while the aldehyde group allowed for rapid derivatization with various hydrazide compounds.

From a synthetic chemistry perspective, advances in metal-catalyzed cross-coupling reactions have expanded the utility of 1228898-23-4. A Nature Communications publication (2023) detailed a novel palladium-catalyzed borylation protocol that enables selective functionalization at the 6-position while preserving the aldehyde group. This methodology has opened new avenues for creating diverse pyridine-based libraries for high-throughput screening in drug discovery programs.

The compound's role in materials science has also emerged as an area of interest. Researchers at MIT (2024) have incorporated 6-bromo-5-chloropyridine-3-carbaldehyde into the design of novel organic semiconductors. The electron-withdrawing nature of the substituents, combined with the planar pyridine core, contributes to desirable electronic properties in these materials, with potential applications in organic photovoltaics.

Recent safety and toxicology studies (Regulatory Toxicology and Pharmacology, 2024) have provided important data on the handling and environmental impact of 1228898-23-4. While the compound shows moderate acute toxicity (LD50 = 320 mg/kg in rats), proper handling procedures and waste management protocols have been established to ensure safe laboratory use. These findings are particularly relevant as industrial-scale applications of this intermediate continue to grow.

Looking forward, the unique reactivity profile of 6-bromo-5-chloropyridine-3-carbaldehyde positions it as a valuable tool for medicinal chemistry. Ongoing research is exploring its use in PROTAC (proteolysis targeting chimera) development and as a warhead in covalent inhibitor design. The compound's commercial availability from multiple suppliers and well-established synthetic routes suggest it will remain a workhorse intermediate in pharmaceutical research for the foreseeable future.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)